GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)  $GRI tinyurl.com/2byp6yj8

$GRI Ph2a biomarker data for IPF looks good and promising. Any comments?

$TGTX, holding my nose and adding some shs below $29. Hope this is a buying opportunity.

$OSTX with lots of good news today. Seems approval to submit rolling BLA likely, and if approved, they get a PVR worth 3x current market cap. Nice. ir.ostherapies.com/news-events/pr…

C'mon $PFE, if $VKTX asking too much, negotiate a CRV and get it done. You know you need it. $LLY

$NYXH only a brief 20% pop on FDA approval. Now up only 9%. Sheesh. Now much reward for holding through that approval risk.

$PHRRF. Interesting market potential for now-approved KETARx if compounders are banned from supplying ketamine.

$PGEN - an early FDA approval tonight courtesy of the new, I mean the old, um, ..., I mean the "new again", director of CBER: Vinay Prasad. Vinay Prasad MD MPH

Most under-rated prediction of todays $VKTX data:

$OSTX at $60M market cap seems like a bargain especially considering on Wednesday they make take a big step in securing a Priority Review Voucher from the FDA worth 3 times their market cap.

Sold all my $OSTX immediately on this. Who holds meeting news for 6 days unless you got hit with a surprise and need to, for example, figure out how to tell investors your plan to pay for a new expensive trial? If they got rolling BLA approval that they expected from the

Not sure what got $ICCM to run after hours tonight, but I took advantage as my GTC sell limit order got filled. Based on their last cc I don't expect an approval decision until late this year.

$OTLK I spit my coffee out reading this in the PR "The CRL included only one deficiency, for a lack of substantial evidence of effectiveness" OMG. That's like the old joke about doctor saying 'the patient is fine, except that he died'.

Nibbling back some $OSTX this morning because they still expect to submit a BLA this year per the PR about warrant exercise. "The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025"

$OSTX I take this confusing PR to mean we are still submitting a BLA even though FDA does not know what guidelines they will use to measure efficacy. Hmmm. "The Company continues to seek direction on which FDA guidance to rely upon with respect to clinical efficacy for the

$REVB out with big news, according to them at least. Anyone looking into this inflammation controlling data?

Selling my $MTSR at $53 - it already priced in the full 1st $5 CVR milestone payout, and the others could be years away. BWDIK.

$INBS 😩 New study required, delays anticipated approval by a year.

$LRMR, well at least the runup and no dip before data showed there was no leak.